Enlivex Reports Positive Allocetra Trial Results in COVID-19 Patients in Severe/Critical Condition

Nes Ziona, Israel, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported positive top-line results of an investigator-initiated clinical trial of AllocetraTM in COVID-19 patients in severe/critical condition.

Original post:
Enlivex Reports Positive Allocetra Trial Results in COVID-19 Patients in Severe/Critical Condition

Silencil Reviews – Tinnitus Relief Support Supplement Debuts

View original post here:
Silencil Reviews – Tinnitus Relief Support Supplement Debuts

Hyloris appoints Dr. Dietmar Aichhorn as Chief Operating Officer

Hyloris appoints Dr. Dietmar Aichhorn as Chief Operating Officer

Link:
Hyloris appoints Dr. Dietmar Aichhorn as Chief Operating Officer

Rubius Therapeutics to Participate in 7th Annual Jefferies Cell Therapy Summit

CAMBRIDGE, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that Laurence Turka, M.D., chief scientific officer, will participate in a fireside chat at the 7th Annual Jefferies Cell Therapy Summit on Monday, October 5, 2020, at 4:00 p.m. ET.

View post:
Rubius Therapeutics to Participate in 7th Annual Jefferies Cell Therapy Summit

ReSPECT Glioblastoma Clinical Trial Data to be Presented at 2020 Society for Neuro-Oncology Annual Meeting

Accepted Abstract will Showcase Clinical Data on Investigational Drug Rhenium NanoLiposomes (RNL™) Accepted Abstract will Showcase Clinical Data on Investigational Drug Rhenium NanoLiposomes (RNL™)

See the article here:
ReSPECT Glioblastoma Clinical Trial Data to be Presented at 2020 Society for Neuro-Oncology Annual Meeting

Cara Therapeutics Appoints Thomas Reilly as Chief Financial Officer

STAMFORD, Conn., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced the appointment of Thomas Reilly as Chief Financial Officer, effective October 1, 2020. Mr. Reilly will be responsible for overseeing the Company’s financial strategy and activities related to accounting, capital markets, and business operations. He joins Cara from Allergan, now part of AbbVie, where he served as Finance Head for the U.S. General Medicine Commercial Business.

Excerpt from:
Cara Therapeutics Appoints Thomas Reilly as Chief Financial Officer

Catalyst Pharmaceuticals Announces Ruling on Lawsuit against the FDA and Intent to Appeal

CORAL GABLES, Fla., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), today reported that the federal judge handling Catalyst's case against the FDA has adopted the previously reported Report and Recommendation of the Magistrate Judge, granted summary judgment in favor of the FDA and Jacobus, and dismissed Catalyst's case. Catalyst is currently reviewing the District Judge's decision, which it believes to be erroneous, and intends to appeal the result to the Eleventh Circuit Court of Appeals.

Visit link:
Catalyst Pharmaceuticals Announces Ruling on Lawsuit against the FDA and Intent to Appeal

Galapagos announces first dosing with Toledo compound GLPG3970 in psoriasis trial

Mechelen, Belgium; 29 September 2020, 22.01 CET – Galapagos NV (Euronext & NASDAQ: GLPG) announces dosing of a first patient in their psoriasis trial, one of three patient trials currently recruiting to evaluate efficacy and safety of Toledo compound GLPG3970. Furthermore, Galapagos plans to unveil the novel Toledo target class and share GLPG3970 Phase 1 data at its inaugural Toledo Roundtable to be held virtually on 27 October 2020.

Original post:
Galapagos announces first dosing with Toledo compound GLPG3970 in psoriasis trial

Chiasma Announces Planned Transition of Former CEO

Mark Fitzpatrick to Step Down as President and Principal Financial Officer Following the Appointment of a New Chief Financial Officer Mark Fitzpatrick to Step Down as President and Principal Financial Officer Following the Appointment of a New Chief Financial Officer

Go here to see the original:
Chiasma Announces Planned Transition of Former CEO

Caladrius Biosciences to Present at the BIO Investor Forum Digital

BASKING RIDGE, N.J., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that its Chief Executive Officer, David J. Mazzo, Ph.D., will present a company overview at the BIO Investor Forum, being held virtually on October 13-15, 2020. This presentation will be available on demand for BIO Investor attendees.

Original post:
Caladrius Biosciences to Present at the BIO Investor Forum Digital